TY - JOUR
T1 - Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy
T2 - A multicenter prospective study
AU - Meucci, Gianmichele
AU - D'Incà, Renata
AU - Maieron, Roberto
AU - Orzes, Nicoletta
AU - Vecchi, Maurizio
AU - Visentini, Daniela
AU - Minoli, Giorgio
AU - Dal Pont, Elisabetta
AU - Zilli, Maurizio
AU - Benedetti, Elvio
AU - Virgilio, Tiziana
AU - Tonutti, Elio
PY - 2010/3
Y1 - 2010/3
N2 - Objectives: To evaluate the role of faecal calprotectin in consecutive outpatients referred for colonoscopy. Methods: Outpatients undergoing colonoscopy at five participating institutions were eligible. Demographic and clinical data were collected. Faecal samples were tested at a single laboratory by means of a commercially available kit. Results: We consecutively enrolled 870 patients. Mean levels of calprotectin were significantly higher in patients with neoplastic and inflammatory disorders when compared with subjects with a normal colonoscopy or trivial endoscopic findings. Elevated calprotectin levels (>50 mg/dl) were detected in 85% of patients with colorectal cancer, and 81% of those with inflammatory conditions but also in 37% of patients with normal or trivial endoscopic findings. In patients referred for chronic diarrhoea, sensitivity and negative predictive value were 100% in detecting either any organic colonic disease. In patients referred for symptoms of "suspected functional origin" sensitivity and negative predictive value for colorectal cancer were also 100%. Conclusions: In unselected outpatients referred for colonoscopy, a single measurement of faecal calprotectin is not sufficiently accurate to identify those with significant colorectal disease. However, a normal result can help rule out organic disease among patients with diarrhoea and those with abdominal pain and/or constipation.
AB - Objectives: To evaluate the role of faecal calprotectin in consecutive outpatients referred for colonoscopy. Methods: Outpatients undergoing colonoscopy at five participating institutions were eligible. Demographic and clinical data were collected. Faecal samples were tested at a single laboratory by means of a commercially available kit. Results: We consecutively enrolled 870 patients. Mean levels of calprotectin were significantly higher in patients with neoplastic and inflammatory disorders when compared with subjects with a normal colonoscopy or trivial endoscopic findings. Elevated calprotectin levels (>50 mg/dl) were detected in 85% of patients with colorectal cancer, and 81% of those with inflammatory conditions but also in 37% of patients with normal or trivial endoscopic findings. In patients referred for chronic diarrhoea, sensitivity and negative predictive value were 100% in detecting either any organic colonic disease. In patients referred for symptoms of "suspected functional origin" sensitivity and negative predictive value for colorectal cancer were also 100%. Conclusions: In unselected outpatients referred for colonoscopy, a single measurement of faecal calprotectin is not sufficiently accurate to identify those with significant colorectal disease. However, a normal result can help rule out organic disease among patients with diarrhoea and those with abdominal pain and/or constipation.
KW - Calprotectin
UR - http://www.scopus.com/inward/record.url?scp=76049109946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76049109946&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2009.07.002
DO - 10.1016/j.dld.2009.07.002
M3 - Article
C2 - 19695969
AN - SCOPUS:76049109946
VL - 42
SP - 191
EP - 195
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 3
ER -